Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Amortization of Deferred Charges (2016 - 2017)

Palisade Bio has reported Amortization of Deferred Charges over the past 5 years, most recently at $12127.0 for Q2 2017.

  • Quarterly Amortization of Deferred Charges fell 15.57% to $12127.0 in Q2 2017 from the year-ago period, while the trailing twelve-month figure was $59781.0 through Dec 2017, down 82.8% year-over-year, with the annual reading at $59781.0 for FY2017, 82.8% down from the prior year.
  • Amortization of Deferred Charges was $12127.0 for Q2 2017 at Palisade Bio, down from $47654.0 in the prior quarter.
  • Over five years, Amortization of Deferred Charges peaked at $231381.0 in Q4 2013 and troughed at $12127.0 in Q2 2017.
  • The 5-year median for Amortization of Deferred Charges is $207350.5 (2014), against an average of $155644.9.
  • Year-over-year, Amortization of Deferred Charges soared 881.51% in 2014 and then plummeted 93.42% in 2016.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $231381.0 in 2013, then decreased by 10.37% to $207388.0 in 2014, then rose by 3.88% to $215440.0 in 2015, then tumbled by 70.29% to $63998.0 in 2016, then tumbled by 81.05% to $12127.0 in 2017.
  • Per Business Quant, the three most recent readings for PALI's Amortization of Deferred Charges are $12127.0 (Q2 2017), $47654.0 (Q1 2017), and $63998.0 (Q4 2016).